NCT00782470

Brief Summary

Understanding how often the bleeding events occur in the subjects who voluntarily decide to switch from prophylaxis to on-demand and in those subjects who remain on prophylaxis. Also look into the consequences of switching treatment in QoL (quality of life), development of target joints, activity level and reasons that might influence the desire to switch.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
38

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Dec 2007

Typical duration for all trials

Geographic Reach
4 countries

10 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2007

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

October 29, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 31, 2008

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2010

Completed
Last Updated

November 3, 2014

Status Verified

October 1, 2014

Enrollment Period

2.9 years

First QC Date

October 29, 2008

Last Update Submit

October 31, 2014

Conditions

Outcome Measures

Primary Outcomes (1)

  • To evaluate the frequency of all bleeds (spontaneous and trauma) during the study

    End of Study

Secondary Outcomes (4)

  • To evaluate the change from baseline in HRQoL (health-related quality of life)

    End of Study

  • To evaluate number of patients that want to return to prophylaxis treatment after having switched to on-demand therapy

    End of Study

  • To evaluate the change from baseline in the Gilbert score

    End of Study

  • To evaluate the number of target joint development

    End of Study

Study Arms (3)

Group 1

Behavioral: Recombinant Factor VIII (Kogenate, BAY 14-2222)

Group 2

Behavioral: Recombinant Factor VIII (Kogenate, BAY 14-2222)

Group 3

Behavioral: Recombinant Factor VIII (Kogenate, BAY 14-2222)

Interventions

Subjects electing to stay on the prophylactic treatment (prospective)

Group 1

Eligibility Criteria

Age14 Years - 29 Years
Sexmale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Cohort 1 - Prospective Prophylaxis Group Cohort 2 - Prospective On-demand Group Cohort 3 - Retrospective On-demand Group

You may qualify if:

  • Severe hemophilia A (\<2%)
  • For subjects who elect staying on Prophylaxis only: Have been on continuous prophylactic treatment for the past 5 years prior to study entry
  • For subjects who elect switching to on-demand only: Have been on continuous prophylactic treatment for the past 5 years, but may have been on intermediate or reduced prophylaxis for the 1-12 months prior to study entry
  • For subjects currently on-demand: a retrospective arm of subjects who have been on continuous prophylactic treatment for at least 5 years and switched to on-demand treatment between 13 and 24 months prior to study entry
  • Current treatment with rFVIII

You may not qualify if:

  • Other known hematological / bleeding disorders other than hemophilia A
  • Participating on another study that may have an impact on bleeding or the objectives of this study
  • Known alcohol and drug abuse

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (10)

Unknown Facility

Duarte, California, 91010, United States

Location

Unknown Facility

Denver, Colorado, 80262, United States

Location

Unknown Facility

Peoria, Illinois, 61614, United States

Location

Unknown Facility

Jefferson City, Missouri, 65109, United States

Location

Unknown Facility

Las Vegas, Nevada, 89109, United States

Location

Unknown Facility

Fort Worth, Texas, 76104, United States

Location

Unknown Facility

Houston, Texas, 77030, United States

Location

Unknown Facility

Many Locations, Canada

Location

Unknown Facility

Many Locations, Germany

Location

Unknown Facility

Many Locations, United Kingdom

Location

Related Publications (1)

  • Manco-Johnson MJ, Sanders J, Ewing N, Rodriguez N, Tarantino M, Humphries T; TEEN/TWEN Study Group. Consequences of switching from prophylactic treatment to on-demand treatment in late teens and early adults with severe haemophilia A: the TEEN/TWEN study. Haemophilia. 2013 Sep;19(5):727-35. doi: 10.1111/hae.12177. Epub 2013 Jun 11.

MeSH Terms

Conditions

Hematologic DiseasesBlood Coagulation Disorders

Interventions

Factor VIIIF8 protein, humanBAY 14-2222

Condition Hierarchy (Ancestors)

Hemic and Lymphatic Diseases

Intervention Hierarchy (Ancestors)

Blood Coagulation FactorsBlood ProteinsProteinsAmino Acids, Peptides, and ProteinsProtein PrecursorsBiological Factors

Study Officials

  • Bayer Study Director

    Bayer

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 29, 2008

First Posted

October 31, 2008

Study Start

December 1, 2007

Primary Completion

November 1, 2010

Study Completion

November 1, 2010

Last Updated

November 3, 2014

Record last verified: 2014-10

Locations